Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World check on new lung cancer drug

NCT ID NCT04575025

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study followed 109 patients with advanced non-small cell lung cancer who had a specific genetic change (MET exon 14 skipping). After the drug Tabrecta was approved, researchers tracked everyone who took it for up to one year. The main goals were to monitor side effects, see how many patients' tumors shrank, and measure how long patients lived without their cancer getting worse.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novartis Investigative Site

    Kōnan, Aichi-ken, 4838704, Japan

  • Novartis Investigative Site

    Nagoya, Aichi-ken, 457-0818, Japan

  • Novartis Investigative Site

    Nagoya, Aichi-ken, 462-0057, Japan

  • Novartis Investigative Site

    Nagoya, Aichi-ken, 464 8681, Japan

  • Novartis Investigative Site

    Okazaki, Aichi-ken, 444-8553, Japan

  • Novartis Investigative Site

    Toyoake, Aichi-ken, 470 1192, Japan

  • Novartis Investigative Site

    Toyota, Aichi-ken, 470-0343, Japan

  • Novartis Investigative Site

    Daisen, Akita, 014-0027, Japan

  • Novartis Investigative Site

    Hachinohe, Aomori, 031-0011, Japan

  • Novartis Investigative Site

    Sakura, Chiba, 285-8741, Japan

  • Novartis Investigative Site

    Fukui-shi, Fukui, 918-8501, Japan

  • Novartis Investigative Site

    Yoshida-gun, Fukui, 910-1193, Japan

  • Novartis Investigative Site

    Fukuoka, Fukuoka, 811-1395, Japan

  • Novartis Investigative Site

    Fukuoka, Fukuoka, 812-8582, Japan

  • Novartis Investigative Site

    Fukuoka, Fukuoka, 814 0180, Japan

  • Novartis Investigative Site

    Iizuka, Fukuoka, 820-0076, Japan

  • Novartis Investigative Site

    Kitakyushu, Fukuoka, 802-0077, Japan

  • Novartis Investigative Site

    Kitakyushu, Fukuoka, 8058508, Japan

  • Novartis Investigative Site

    Kitakyushu, Fukuoka, 806-8501, Japan

  • Novartis Investigative Site

    Fukushima, Fukushima, 960 1295, Japan

  • Novartis Investigative Site

    Ōgaki, Gifu, 503-8502, Japan

  • Novartis Investigative Site

    Higashihiroshima, Hiroshima, 739-0041, Japan

  • Novartis Investigative Site

    Sapporo, Hokkaido, 003-0804, Japan

  • Novartis Investigative Site

    Akashi, Hyōgo, 673-8558, Japan

  • Novartis Investigative Site

    Himeji, Hyōgo, 670-8520, Japan

  • Novartis Investigative Site

    Nishinomiya, Hyōgo, 663 8501, Japan

  • Novartis Investigative Site

    Tsuchiura, Ibaraki, 300-0028, Japan

  • Novartis Investigative Site

    Tsukuba, Ibaraki, 305-8558, Japan

  • Novartis Investigative Site

    Kan’onjichō, Kagawa-ken, 769-1695, Japan

  • Novartis Investigative Site

    Sakaidechō, Kagawa-ken, 762-8550, Japan

  • Novartis Investigative Site

    Takamatsu, Kagawa-ken, 760-0017, Japan

  • Novartis Investigative Site

    Fujisawa, Kanagawa, 251-8550, Japan

  • Novartis Investigative Site

    Kawasaki, Kanagawa, 216-8511, Japan

  • Novartis Investigative Site

    Sagamihara, Kanagawa, 252-0375, Japan

  • Novartis Investigative Site

    Yokohama, Kanagawa, 220-8521, Japan

  • Novartis Investigative Site

    Yokohama, Kanagawa, 221-0855, Japan

  • Novartis Investigative Site

    Yokohama, Kanagawa, 232 0024, Japan

  • Novartis Investigative Site

    Yokohama, Kanagawa, 234-0054, Japan

  • Novartis Investigative Site

    Yokohama, Kanagawa, 236 0037, Japan

  • Novartis Investigative Site

    Tsu, Mie-ken, 514-8507, Japan

  • Novartis Investigative Site

    Yokkaichi, Mie-ken, 510-8567, Japan

  • Novartis Investigative Site

    Miyakonojō, Miyazaki, 885-0014, Japan

  • Novartis Investigative Site

    Matsumoto, Nagano, 390-8621, Japan

  • Novartis Investigative Site

    Nagasaki, Nagasaki, 852-8501, Japan

  • Novartis Investigative Site

    Kurashiki, Okayama-ken, 701-0192, Japan

  • Novartis Investigative Site

    Okayama, Okayama-ken, 700-8558, Japan

  • Novartis Investigative Site

    Kishiwada, Osaka, 596-8501, Japan

  • Novartis Investigative Site

    Osaka, Osaka, 534-0021, Japan

  • Novartis Investigative Site

    Osaka, Osaka, 540-0006, Japan

  • Novartis Investigative Site

    Osaka, Osaka, 541-8567, Japan

  • Novartis Investigative Site

    Osaka, Osaka, 543-8555, Japan

  • Novartis Investigative Site

    Saga, Saga-ken, 849-8501, Japan

  • Novartis Investigative Site

    Kawaguchi, Saitama, 332-8558, Japan

  • Novartis Investigative Site

    Kumagaya, Saitama, 360-0197, Japan

  • Novartis Investigative Site

    Saitama, Saitama, 330 8503, Japan

  • Novartis Investigative Site

    Saitama, Saitama, 330-8553, Japan

  • Novartis Investigative Site

    Izumo, Shimane, 693 8501, Japan

  • Novartis Investigative Site

    Hamamatsu, Shizuoka, 431-3192, Japan

  • Novartis Investigative Site

    Bunkyo Ku, Tokyo, 113-8431, Japan

  • Novartis Investigative Site

    Chuo Ku, Tokyo, 104 0045, Japan

  • Novartis Investigative Site

    Edogawa City, Tokyo, 133-0052, Japan

  • Novartis Investigative Site

    Kiyose, Tokyo, 204-8585, Japan

  • Novartis Investigative Site

    Koto Ku, Tokyo, 135 8550, Japan

  • Novartis Investigative Site

    Minato, Tokyo, 108-0073, Japan

  • Novartis Investigative Site

    Minato Ku, Tokyo, 105-8470, Japan

  • Novartis Investigative Site

    Minato-ku, Tokyo, 105-8471, Japan

  • Novartis Investigative Site

    Shibuya City, Tokyo, 150-8935, Japan

  • Novartis Investigative Site

    Shinjuku Ku, Tokyo, 160-0023, Japan

  • Novartis Investigative Site

    Tama, Tokyo, 206-8512, Japan

  • Novartis Investigative Site

    Toyama, Toyama, 930-0194, Japan

  • Novartis Investigative Site

    Higashi Okitama, Yamagata, 9920601, Japan

  • Novartis Investigative Site

    Ube, Yamaguchi, 755-0241, Japan

  • Novartis Investigative Site

    Aomori, 030 8553, Japan

  • Novartis Investigative Site

    Chiba, 261-0001, Japan

  • Novartis Investigative Site

    Hiroshima, 734 8530, Japan

  • Novartis Investigative Site

    Kumamoto, 860-8556, Japan

  • Novartis Investigative Site

    Kumamoto, 861-4193, Japan

  • Novartis Investigative Site

    Osaka, 530 0005, Japan

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER